Investments overview
185 investments
Title Sort descending | Period | Programme | |
---|---|---|---|
A coherent approach to virtual assessments of structural robustness | 2019 - 2022 | Industrial Researcher
|
|
A coherent approach to virtual assessments of structural robustness
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
54.86 Invested
1.1 mill. Budget
2.0 mill. Novo Nordisks patienter er dybt afhængige af at have adgang til innovative devices med høj pålidelighed. Øget brug af varians-baserede simuleringer i udviklingsprocessen ville kunne give design ingeniørerne en øget forståelse af hvordan devicet vil fungere i hele udfaldsområdet, dvs. inkl. varians fra produktion og brug. Udvikling af en proces og metoder til at lave sådanne simuleringer vil muliggøre hurtig udvikling af innovative og pålidelige devices, hvilket kommer patienterne til gode.
Partners
Novo Nordisk A/S Technical University of Denmark People
Aktiv
Read more about the project
| |||
A molecular display platform for screening and direct selection of functionally active peptides | 2019 - 2021 | Industrial Researcher
|
|
A molecular display platform for screening and direct selection of functionally active peptides
Period
2019 - 2021
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
45.61 Invested
828.000 Budget
1.8 mill. Peptider er en lovende klasse af molekyler til behandling af en lang række sygdomme. I nærværende projekt ønsker vi at udvikle en ny peptid-screenings platform som muliggør direkte selektion af enkelte funktionelt aktive peptider fra peptid-biblioteker som indeholder op til milliarder af individuelle peptider.
Det forventes at etablering af en sådan screenings platform vil øge mulighederne for hurtigere at finde terapeutiske peptider med nye virkningsmekanismer og ønskede egenskaber.
Partners
ZEALAND PHARMA A/S, Danmarks Tekniske Universitet People
Aktiv
Read more about the project
| |||
A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals | 2019 - 2022 | Industrial Researcher
|
|
A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
47.06 Invested
1.1 mill. Budget
2.3 mill. Biologiske lægemidler har en række unikke egenskaber, der har ført til gennembrud inden for behandling af mange sygdomme. Udviklingen af denne type lægemidler er imidlertid forbundet med store udfordringer, da de aktive lægemiddelstoffer kan være ustabile eller forårsage immunrespons i patienten. I dette projekt adresseres disse problemstillinger gennem udvikling af en ny banebrydende analyseteknologi baseret på tynde kapillarrør. Teknologien vil ultimativt fører til nye og sikrere lægemidler.
Partners
FIDA-TECH ApS, Københavns Universitet People
Aktiv
Read more about the project
| |||
A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation | 2019 - 2020 | Innofounder
|
|
A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation
Period
2019 - 2020
Region
Program
Innofounder Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
460.000 Budget
460.000 Today 12 mil. diabetics inject human insulin with a syringe as modern devices are unaffordable. A durable and disposable combined device is a cost-neutral simple alternative with commercial potential.
Partners
Ole Kjerkegaard Nielsen People
Aktiv
Read more about the project
| |||
Accelerating vaccine development through a deep learning and probabilistic programming approach to protein structure prediction | 2019 - 2022 | Industrial Researcher
|
|
Accelerating vaccine development through a deep learning and probabilistic programming approach to protein structure prediction
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
42.6 Invested
1.1 mill. Budget
2.5 mill. Evaxion develops vaccines against bacterial pathogens by discovering protective proteins using an in-house AI platform called EDEN. These proteins are cumbersome to design and develop for clinical testing, with significant preclinical development costs. We aim to greatly accelerate this process by generating improved structural models of the identified proteins using novel methodologies within deep learning and probabilistic programming, thus allowing the generation of clinically ready designs.
Partners
EVAXION BIOTECH A/S, Københavns Universitet People
Aktiv
Read more about the project
| |||
ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars | 2019 - 2020 | Innobooster
|
|
ACD-plugin – a disinfective easy-to-install solution for improvement of air quality in cars
Period
2019 - 2020
Region
Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
490.050 Budget
1.5 mill. Lugtgener fra bilens ventilationsanlæg pga. akkumulering af bakterier og svamp er et velkendt problem, som kan have konsekvenser for sundhed og indeklima. ACD ApS har udviklet en innovativ løsning, ACD-Plugin, som er et lille UVC LED-lys i form af et plugin, tilpasset snævre og sværttilgængelige ventilationssystemer, som det der findes i biler. Den desinficerende effekt af UVC forstærkes af en antibakteriel TiO2-behandling, som med påvist effekt udraderer akkumulerede patogene.
Partners
ACD ApS People
Aktiv
Read more about the project
| |||
ACOUPLAST | 2019 - 2022 | International collaborations
|
|
ACOUPLAST
Period
2019 - 2022
Region
Program
Internationalt samarbejde Area
Biotek, Medico og Sundhed Investment
Percentage
24.2 Invested
2.8 mill. Budget
11.5 mill. ACOUPLAST aims to reach a 900M€/year market opportunity with the development of a polymer acoustofluidic chip for high-performing, fast and cost-effective plasma separation, to enable healthcare and veterinary Point-of-Care (PoC) diagnostics. Targeting life science companies, we will deliver AcouPlast chip modules for integration in single-use test cartridges. The solution is a recent research breakthrough by DTU Physics, experimentally validated by ACS, resulting in a patent application.
Partners
DTU, Ortofon A/S, AcouSort AB, Lund University People
Aktiv
Read more about the project
| |||
ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs) | 2019 - 2020 | Innobooster
|
|
ADCendo ApS - A biotech spinout developing novel anti-cancer drugs in the form of antibody drug conjugates (ADCs)
Period
2019 - 2020
Region
Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
30 Invested
483.600 Budget
1.6 mill. ADCendo ApS is a biotech spin-out established in 2017, with a vision to develop new anti-cancer drugs directed at a novel target, in the form of antibody-drug conjugates (ADCs). Current activities revolve around optimization of ADCendos first drug candidate, involving collaboration with international pharma companies. Thereby, this InnoBooster project will enable identification of a lead candidate, and contribute with key progress involving international knowledge- and technology providers.
Partners
ADCendo ApS People
Aktiv
Read more about the project
| |||
ADCendo ApS - first-in-class targeted cancer drugs | 2019 - 2020 | Innofounder
|
|
ADCendo ApS - first-in-class targeted cancer drugs
Period
2019 - 2020
Region
Program
Innofounder Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
460.000 Budget
460.000 In 40 years, only one drug, recently failed, has been approved for first-line therapy of sarcoma cancer. Through targeted therapy exploiting a novel antigen, ADCendo seeks to address this unmet need.
Partners
Christoffer Fagernæs Nielsen People
Aktiv
Read more about the project
| |||
Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D | 2019 - 2024 | Grand Solutions
|
|
Adherence through cloud-based Personalised Treatment for Type 2 Diabetes ADAPT-T2D ADAPT-T2D
Period
2019 - 2024
Region
Program
Grand Solutions Area
Biotek, Medico og Sundhed Investment
Percentage
52.12 Invested
17.1 mill. Budget
32.9 mill. We propose cloud-based, personalised treatment to improve real-world adherence and outcomes for type 2 diabetes (T2D) patients. Adherence inhibits most T2D patients from reaching treatment targets. This impacts health, quality of life and cost society. To support care teams and empower patients to self-manage, we integrate data from continuous glucose monitors, connected insulin pens and activity trackers and provide real-time, personalised treatment guidance, data-derived insights, hypoglycemia warnings and dose reminders. Methods include large-scale data collection, development of a high-fidelity T2D model and required algorithms, and clinical feasibility testing of the full solution.
Partners
Region Sjælland, Novo Nordisk A/S, Aalborg University (Department of Electronic Systems), Technical University of Denmark (DTU Compute, Scientific computing), University of Cambridge (Department of Paediatrics), Glooko AB, Aalborg Universitetshospital (Region Nordjylland) People
Aktiv
Read more about the project
| |||
Advanced characterization of large scale fermentations | 2019 - 2021 | Industrial Researcher
|
|
Advanced characterization of large scale fermentations
Period
2019 - 2021
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
46.94 Invested
828.000 Budget
1.8 mill. The lack of knowledge of the heterogeneous process condition in the large-scale reactors is a major challenge for bioindustries. This project aims to tackle this problem by establishing validated computational simulations with a novel real-time measurement technology (free-floating sensor device by Freesense) for large-scale fermentations. These simulations could be provided to the bioindustry as a valuable tool to design, evaluate, control and optimize various processes.
Partners
Freesense Aps, Danmarks Tekniske Universitet People
Aktiv
Read more about the project
| |||
Advanced modelling for prediction and control of related substances in an antibiotic fermentation processes | 2019 - 2022 | Industrial Researcher
|
|
Advanced modelling for prediction and control of related substances in an antibiotic fermentation processes
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
47.73 Invested
1.1 mill. Budget
2.2 mill. For at kunne hjælpe så mange patienter som muligt, er det nødvendigt at nedbringe omkostningerne ved lægemiddelproduktion. Det er dyrt og risikabelt at foretage ændringer i de farmaceutiske produktionsprocesser. En af de bedste måder at mindske risici er udviklingen af effektive forudsigelige procesmodeller. I dette projekt vil vi udvikle nye og innovative modeller ved hjælp af store datasæt med det formål at minimere produktionen af uønskede stoffer ved proces skalaer over 25 kubikmeter.
Partners
LEO PHARMA A/S, Danmarks Tekniske Universitet People
Aktiv
Read more about the project
| |||
Advancing biological solutions for biofouling | 2019 - 2022 | Industrial Researcher
|
|
Advancing biological solutions for biofouling
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
56.02 Invested
1.1 mill. Budget
1.9 mill. Bakterier i biofilm er indkapslet i en beskyttende matrix, og de tåler derfor biocider og antibiotika. Formålet med dette projekt er at udvikle en high-throughput screenings-platform til identifikation af enzymkombinationer som nedbryder biofilm. Samtidig opnås viden om hvilke makromolekyler der beskytter bakterierne mod biocider. Projektet vil give både ny viden om biofilms sammensætning, og tage det første skridt mod udvikling af biocid-frie enzymbaserede løsninger til biofilm kontrol.
Partners
Novozymes A/S Aarhus University People
Aktiv
Read more about the project
| |||
Advancing KP405 - A Novel, First-in-Class, Disease Modifying Treatment for Parkinson's Disease | 2019 - 2020 | Innobooster
|
|
Advancing KP405 - A Novel, First-in-Class, Disease Modifying Treatment for Parkinson's Disease
Period
2019 - 2020
Region
Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
4.0 mill. Budget
12.0 mill. Efficacy of KP405 has been extensively characterized in multiple animal models of neurodegeneration. This proposal has been submitted with the purpose to advance the development of KP405 to human trials. Specifically, this proposal entails completion of the manufacturing and toxicity studies of KP405 in animals, required for regulatory submission of an investigational new drug (IND)/clinical trial application (CTA) and subsequent evaluation of safety, tolerability, and efficacy in humans.
Partners
Kariya Pharmaceuticals IVS People
Aktiv
Read more about the project
| |||
Affective Design for improved Health Outcomes for Rheumatology Patients using Digital Health Technology | 2019 - 2022 | Industrial Researcher
|
|
Affective Design for improved Health Outcomes for Rheumatology Patients using Digital Health Technology
Period
2019 - 2022
Region
Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
51.29 Invested
1.1 mill. Budget
2.1 mill. Sundhedsøkonomiske udregninger i Danmark indikerer at de samfundsmæssige udgifter til gigtpatienter beløber sig til op mod 3,7 mia DKK årligt. Dette projekt bidrager til at forbedre livskvaliteten for gigtpatienter gennem et affekt-drevet design af en self-tracking app, der giver patienter mulighed for at samle og dele data om deres helbred og følelsesliv. Dette kan medvirke til at forbedre længerevarende behandlingsforløb og skabe vækst i nye datadrevne forretningsområder hos Daman globalt.
Partners
DAMAN P/S IT University of Copenhagen People
Aktiv
Read more about the project
|